Literature DB >> 8234010

Cardiovascular actions of angiotensin(1-7).

I F Benter1, D I Diz, C M Ferrario.   

Abstract

Angiotensin(1-7) had a compound effect on blood pressure of pithed Sprague-Dawley rats. The initial phase of the response consisted of an increase in MAP of short duration and independent of injected dose, followed by a decline of arterial pressure to values below baseline. Both the magnitude (range: -4 +/- 1 to -13 +/- 1 mmHg) and the duration (range: 83 +/- 13 to 255 +/- 17 s) of the depressor response correlated with the dose of peptide. Indomethacin (5 mg/kg) eliminated the depressor component. Only [Sar1,Thr8]Ang II inhibited the effect of Ang(1-7) completely. We conclude that angiotensin(1-7) possesses myotonic actions that are in part related to release of vasodilator prostaglandins through an angiotensin receptor other than AT1 or AT2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234010     DOI: 10.1016/0196-9781(93)90097-z

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  38 in total

Review 1.  Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology.

Authors:  Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 3.  ACE2: more of Ang-(1-7) or less Ang II?

Authors:  Carlos M Ferrario
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

Review 4.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

Review 5.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 6.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 7.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

Review 8.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

9.  Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Norihito Moniwa; K Bridget Brosnihan; Jan Wysocki; Daniel Batlle; Carlos M Ferrario
Journal:  Am J Hypertens       Date:  2013-03-04       Impact factor: 2.689

10.  Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas.

Authors:  Concepción Peiró; Susana Vallejo; Florian Gembardt; Erika Palacios; Susana Novella; Verónica Azcutia; Leocadio Rodríguez-Mañas; Carlos Hermenegildo; Carlos F Sánchez-Ferrer; Thomas Walther
Journal:  J Physiol       Date:  2013-03-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.